s
Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
08-02-2024, 09:15
– The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), […] L'articolo Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing proviene da La Ragione.
CONTINUA A LEGGERE
12
0
0
Guarda anche
La Ragione
17:56
**Mattarella: funzionamento democrazia oggi in difficoltà**
La Ragione
17:55